|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.09 EUR | +0.98% |
|
+1.33% | -13.89% |
| Dec. 10 | MedTech Stocks Diverge Following Exane Report: 'A Split 2026' | DP |
| Dec. 10 | Telix Pharmaceuticals Limited and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration | CI |
| Capitalization | 49.13B 57.67B 45.89B 43.18B 79.49B 5,223B 86.84B 536B 208B 2,462B 216B 212B 8,983B | P/E ratio 2026 * |
20.7x | P/E ratio 2027 * | 17.8x |
|---|---|---|---|---|---|
| Enterprise value | 60.08B 70.52B 56.12B 52.8B 97.21B 6,387B 106B 655B 254B 3,011B 265B 259B 10,985B | EV / Sales 2026 * |
2.48x | EV / Sales 2027 * | 2.29x |
| Free-Float |
23.56% | Yield 2026 * |
2.31% | Yield 2027 * | 2.74% |
Last Transcript: Siemens Healthineers AG
| 1 day | +0.98% | ||
| 1 week | +1.33% | ||
| Current month | +2.92% | ||
| 1 month | +1.78% | ||
| 3 months | -7.41% | ||
| 6 months | -3.42% | ||
| Current year | -13.89% |
| 1 week | 42.83 |  | 44.1 |
| 1 month | 40.97 | | 44.21 |
| Current year | 40.97 | | 58.48 |
| 1 year | 40.97 | | 58.48 |
| 3 years | 40.97 | | 58.48 |
| 5 years | 40.12 | | 67.66 |
| 10 years | 28.5 | | 67.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bernhard Montag
CEO | Chief Executive Officer | 56 | 2015-01-31 |
Jochen Schmitz
DFI | Director of Finance/CFO | 59 | 2017-11-30 |
Peter Schardt
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 2018-02-28 | |
| Chairman | 64 | 2019-11-30 | |
Marion Helmes
BRD | Director/Board Member | 60 | 2018-02-28 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 1.11% | 962 M€ | -.--% | - |
| 1.11% | 1 M€ | +54.47% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.98% | +1.33% | -17.59% | -13.52% | 57.67B | |
| -1.14% | -0.09% | +8.61% | +0.16% | 215B | |
| -0.92% | -5.74% | +0.51% | +92.49% | 192B | |
| -2.60% | +0.04% | -3.64% | -18.20% | 160B | |
| +0.90% | -5.07% | +2.74% | +96.14% | 137B | |
| -1.38% | -3.61% | +13.31% | +9.37% | 48.21B | |
| -2.23% | -3.99% | +0.49% | -11.40% | 39.54B | |
| -2.43% | -1.76% | +3.53% | - | 38.25B | |
| -0.05% | -1.67% | +5.76% | +12.77% | 36.77B | |
| +2.07% | -1.27% | -22.90% | -36.04% | 34.25B | |
| Average | -0.68% | -2.07% | -0.92% | +14.64% | 95.91B | |
| Weighted average by Cap. | -0.87% | -2.29% | +0.99% | +28.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.22B 28.43B 22.63B 21.29B 39.19B 2,575B 42.82B 264B 102B 1,214B 107B 104B 4,429B | 25.71B 30.17B 24.01B 22.59B 41.59B 2,733B 45.44B 280B 109B 1,288B 113B 111B 4,700B |
| Net income | 2.31B 2.71B 2.16B 2.03B 3.73B 245B 4.08B 25.16B 9.76B 116B 10.16B 9.95B 422B | 2.75B 3.23B 2.57B 2.42B 4.45B 292B 4.86B 29.96B 11.62B 138B 12.1B 11.85B 502B |
| Net Debt | 10.95B 12.85B 10.23B 9.62B 17.72B 1,164B 19.36B 119B 46.31B 549B 48.23B 47.21B 2,002B | 9.86B 11.58B 9.21B 8.67B 15.96B 1,049B 17.43B 108B 41.71B 494B 43.44B 42.53B 1,803B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-12 | 44.03 € | +0.94% | 1,036,857 |
| 25-12-11 | 43.62 € | +1.47% | 502,635 |
| 25-12-10 | 42.99 € | -1.85% | 1,134,338 |
| 25-12-09 | 43.80 € | +1.11% | 1,296,277 |
| 25-12-08 | 43.32 € | -0.44% | 2,552,863 |
Delayed Quote Xetra, December 12, 2025 at 03:38 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SHL Stock
Select your edition
All financial news and data tailored to specific country editions
